Mike Ambrogi joined Novocure in 2006 and serves as Chief Operating Officer. Mr. Ambrogi has overall responsibility for our ongoing operations, engineering, manufacturing and service, and human resources activities worldwide. From 1991 to 2006, Mr. Ambrogi worked for Deka Research and Development Corporation, inventor Dean Kamen’s private R&D firm, last serving as General Manager. Mr. Ambrogi led Deka’s teams on many products including the Baxter HomeChoice peritoneal dialysis machine, the Davol Hydroflex surgical irrigation device, the Cordis Crowne Stent and the Johnson & Johnson IBOT 3000 mobility system. Earlier in his career, Mr. Ambrogi was a consultant with McKinsey & Company. Mr. Ambrogi holds a B.S. in mechanical engineering from the Massachusetts Institute of Technology.
clinical trialsOur mechanism of action is broadly applicable across a variety of solid tumors.
novocuretrial.comThe science of Tumor Treating Fields extends beyond glioblastoma. We are conducting clinical trials in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.